Research into rare blood cancers called myeloproliferative neoplasms goes global
MPN News | 12/4/19
MPN advocacy organizations are working together across borders to ensure that people living with polycythemia vera, essential thrombocythemia and myelofibrosis will have their treatment needs met by investing in research.
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis
MPN News | 11/21/19
Sierra Oncology announced today that it has launched the Phase 3 MOMENTUM clinical trial for Myelofibrosis patients
Call for MPN drug to be approved in Australia
MPN News | 11/20/19
"There's actually an even longer-acting version of the drug, an ultra-long-acting version, which has been approved in Europe but not Australia, and we'd like to see that approved here."
Pegylated Interferon Benefits High-Risk MPNs Previously Treated With Hydroxyurea
MPN News | 11/07/19
According to a study published in Blood, Pegylated interferon proved to be effective for patients with high-risk ET and PV.
New Clinical Trials Available for MPN Patients
MPN News | 11/06/19
Vactosertib and PRT543 are now available.
Patient Power's MPN Patient Survey
MPN News | 10/21/19
As researchers around the world seek to accelerate progress in medicine it's important for patients to share their stories to promote greater understanding. Patient Power has partnered with Dr. Naveen Pemmaraju to find out more about how patients use online resources to guide their car
New Trial Recruiting Primary, Post-PV, and Post-ET Myelofibrosis Patients
MPN News | 10/15/19
CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating PACRITINIB in patients with MF.
The Fall 2019 Newsletter is Here
MPN News | 10/3/19
Your copy of the Fall 2019 Newsletter from the MPN Research Foundation is now available.
Pegylated Interferon Leads to High Response Rates in ET & PV After Hydroxyurea
MPN News | 10/1/19
ASH Clinical News reports on the results of an open-label, phase II clinical trial published in Blood.
Today is Rare Cancer Day!
MPN News | 10/1/19
The big day is here - Rare Cancer Day! Launched by the National Organization for Rare Disorders (NORD) and the NORD Rare Cancer Coalition, the goal of #RareCancerDay is to raise critical awareness of rare cancers and the need for greater research funding and patient support.
Geron Receives Fast Track Designation to Imetelstat for Myelofibrosis
MPN News | 9/30/19
More possible good news for upcoming therapies for myeloproliferative neoplasms. Geron was granted fast-track designation by FDA for imetelstat, which they have pursued in people with Intermediate-2 Myelofibrosis
MPN Research Foundation Announces 2019-2020 Grantees for MPN Challenge Grant program
MPN News | 9/23/19
The MPN Research Foundation is thrilled to announce the award of seven new projects as part of the MPN Challenge Grant program, a partnership between MPNRF and The Leukemia & Lymphoma Society. The following projects applied and reviewed in a competitive, peer-reviewed process that took place this past July in Chicago.
Pegasys users may now access resources to help with reimbursement issues through Genentech
MPN News | 9/10/19
For more information about the Genentech Patient Foundation and to learn if a patient receiving a Genentech product (such as Pegasys) is eligible to receive support, please visit www.gene.com/patients/patient-foundation or call the Patient Resource Center at 877-GENENTECH.
Patient Advocates Take Aim at Progression in Myeloproliferative Neoplasms
MPN News | 9/10/19
Through a one-year pilot grant, the MPN Research Foundation (MPNRF) will provide funding to Dr. Ann Mullally and Dana-Farber Cancer Institute's Center for Prevention of Progression (CPOP) to study the genomic basis for MPN disease progression